Therapy Detail

Therapy Name AMG 337
Synonym
Therapy Description

AMG 337 selectively inhibits c-MET and may induce cell death in tumors overexpressing c-MET or expressing constitutively activated c-MET (PMID: 30366938).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
AMG 337 MET Inhibitor 51 AMG 337 selectively inhibits c-MET and may induce cell death in tumors overexpressing c-MET or expressing constitutively activated c-MET (PMID: 30366938).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
MET amp gastroesophageal cancer predicted - sensitive AMG 337 Phase I Actionable In a Phase I trial, AMG 337 treatment resulted in complete response in 10% (1/10), partial response in 40% (4/10), and stable disease in 20% (2/10) of patients with MET amplified gastroesophageal cancer (J Clin Oncol 33, no. 3_suppl (January 20 2015) 1-1; NCT01253707). detail...
KRAS G12D MET amp esophagus adenocarcinoma predicted - resistant AMG 337 Case Reports/Case Series Actionable In a clinical case study, a patient with a MET amplified adenocarcinoma of the distal esophagus responded to AMG 337 treatment for 2 years, but developed resistance upon emergence of KRAS G12D (PMID: 26432108). 26432108
ERBB2 amp MET amp gastric adenocarcinoma predicted - resistant AMG 337 Case Reports/Case Series Actionable In a clinical case study, a patient with ERBB2 (HER2) and MET co-amplified gastric adenocarcinoma did not respond to AMG 337 therapy (PMID: 26432108). 26432108
MET amp hepatocellular carcinoma sensitive AMG 337 Preclinical - Pdx & cell culture Actionable In a preclinical study, AMG 337 inhibited Met phosphorylation and growth of hepatocellular carcinoma (HCC) cell lines with MET amplification in culture, and inhibited tumor growth in MET-amplified HCC patient-derived xenograft models (PMID: 27196749). 27196749
MET amp Advanced Solid Tumor conflicting AMG 337 Phase I Actionable In a Phase I trial, AMG 337 treatment resulted in an objective response rate (ORR) of 29.6% (8/27) and a median duration of response (mDOR) of 197 days in patients with MET amplified advanced solid tumors, compared to an ORR of 9.9% (11/111) and mDOR of 202 days in all patients (PMID: 30425090; NCT01253707). 30425090
MET amp Advanced Solid Tumor conflicting AMG 337 Clinical Study - Cohort Actionable In a retrospective study, treatment with Met inhibitors, including AMG 337 or EMD 1204831, resulted in stable disease in 29% (2/7) of advanced solid tumor patients harboring MET amplification while 10% (14/134) of MET non-amplified patients achieved partial response (PMID: 25326232). 25326232
MET amp esophagus adenocarcinoma predicted - sensitive AMG 337 Case Reports/Case Series Actionable In a clinical case study, a patient with MET amplified esophageal adenocarcinoma had a partial response to AMG 337 therapy after 2 months of treatment (PMID: 26432108). 26432108
MET amp esophagus adenocarcinoma predicted - sensitive AMG 337 Case Reports/Case Series Actionable In a Phase I trial, AMG 337 treatment resulted in a complete response in a patient with MET amplified esophagus adenocarcinoma at week 33 (PMID: 30425090; NCT01253707). 30425090
MET amp gastroesophageal adenocarcinoma predicted - sensitive AMG 337 Phase II Actionable In a Phase II trial, AMG 337 treatment resulted in an objective response rate of 18% (8/45, 8 partial responses) and stable disease in 36% (16/45) of patients with MET-amplified gastroesophageal adenocarcinoma (PMID: 30366938; NCT02016534). 30366938
MET amp stomach cancer sensitive AMG 337 Preclinical - Cell line xenograft Actionable In a preclinical study, AMG 337 inhibited growth of gastric cancer cell lines in culture, and inhibited growth and induced regression of tumors in MET-amplified gastric cancer cell line xenograft models (PMID: 27196782). 27196782
MET amp lung non-small cell carcinoma predicted - sensitive AMG 337 Case Reports/Case Series Actionable In a Phase I trial, AMG 337 treatment resulted in a partial response in a patient with MET amplified non-small cell lung cancer (PMID: 30425090; NCT01253707). 30425090
MET amp lung non-small cell carcinoma predicted - sensitive AMG 337 Case Reports/Case Series Actionable In a Phase II trial, AMG 337 treatment resulted in no objective response (0/3) and only stable disease in 33% (1/3) of patients with MET-amplified non-small cell lung cancer (PMID: 30366938; NCT02016534). 30366938
MET amp lung cancer sensitive AMG 337 Preclinical - Cell culture Actionable In a preclinical study, AMG 337 inhibited growth of MET-amplified lung cancer cell lines in culture (PMID: 27196782). 27196782
ERBB2 amp TP53 R158H gastric adenocarcinoma predicted - resistant AMG 337 Clinical Study Actionable In a clinical case study, a patient with gastric adenocarcinoma containing amplification of ERBB2 (HER2) and a TP53 R158H mutation progressed and developed metastases while being treated with AMG 337 (PMID: 26432108). 26432108
MET over exp malignant mesothelioma predicted - sensitive AMG 337 Case Reports/Case Series Actionable In a Phase I trial, AMG 337 treatment resulted in a partial response in a patient with mesothelioma with MET overexpression by IHC (PMID: 30425090; NCT01253707). 30425090
Unknown unknown Advanced Solid Tumor not applicable AMG 337 Phase I Actionable In a Phase I trial, AMG 337 demonstrated safety and preliminary efficacy in patients with a variety of advanced solid tumors (J Clin Oncol 33, 2015 (suppl; abstr e13538)). detail...
KRAS G12A MET amp lung cancer resistant AMG 337 Preclinical - Cell culture Actionable In a preclinical study, a MET-amplified lung cancer cell line harboring KRAS G12A was not sensitive to growth inhibition by AMG 337 in culture (PMID: 27196782). 27196782
Clinical Trial Phase Therapies Title Recruitment Status
NCT02344810 Phase Ib/II AMG 337 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer Withdrawn
NCT03147976 Phase II AMG 337 QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors Recruiting
NCT03132155 Phase II AMG 337 QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma Recruiting
NCT01253707 Phase I AMG 337 A Study of AMG 337 in Subjects With Advanced Solid Tumors Completed
NCT02016534 Phase II AMG 337 Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors Terminated